高级检索
当前位置: 首页 > 详情页

Gonioscopy-assisted Transluminal Trabeculotomy (GATT) combined phacoemulsification surgery: Outcomes at a 2-year follow-up

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

机构: [1]Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China [2]Capital Med Univ, Beijing Tongren Hosp, Beijing Tongren Eye Ctr, Beijing, Peoples R China
出处:
ISSN:

摘要:
Background/Objectives This study aimed to provide a 24-month follow-up on the surgical success and safety of gonioscopy-assisted transluminal trabeculotomy (GATT) combined with phacoemulsification and intraocular lens (IOL) implantation in the treatment of patients with primary open-angle glaucoma (POAG) combined cataract. Subjects/Methods We included 124 consecutive cases of POAG with microcatheter-assisted GATT or GATT combined with phacoemulsification and IOL implantation at Beijing Tongren Eye Centre between October 2019 and November 2020. Main outcome measures included surgical success rate, changes in IOP, number of antiglaucoma medications, best corrected visual acuity (BCVA), postoperative complications at baseline, and follow-up period of up to 24 months. Results In total, 58 eyes received GATT combined with phacoemulsification surgery and 66 eyes received GATT alone. The overall qualified success rate was 86.21% for eyes with GATT combined with phacoemulsification surgery, and 83.48% for eyes with GATT only at 24 months. IOP was reduced from 26.40 +/- 6.37 mmHg on 3.12 +/- 0.80 medications preoperatively to 14.61 +/- 2.28 mmHg on 0.27 +/- 0.71 medications at 12 months and 16.08 +/- 2.38 mmHg on 0.45 +/- 0.96 medications at 24 months after combined surgery. Additionally, mean BCVA improved from 0.75 +/- 0.43 logMAR units preoperatively to 0.22 +/- 0.18 logMAR units 24 months after combined surgery. No vision-threatening complications occurred during the 24-month follow-up. Conclusions The 24-month follow-up results of our study suggest that GATT combined with cataract surgery is a safe and effective treatment for decreasing IOP and number of medications in patients with POAG combined cataract.

基金:

基金编号: 81730027 82130029

语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 3 区 医学
小类 | 3 区 眼科学
最新[2025]版:
大类 | 3 区 医学
小类 | 3 区 眼科学
JCR分区:
出版当年[2021]版:
Q1 OPHTHALMOLOGY
最新[2023]版:
Q2 OPHTHALMOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者机构: [1]Capital Med Univ, Beijing Tongren Hosp, Beijing Inst Ophthalmol, Beijing, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:23549 今日访问量:0 总访问量:1282 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学附属北京同仁医院 技术支持:重庆聚合科技有限公司 地址:北京市东城区东交民巷1号(100730)